- Home
- Publications
- Publication Search
- Publication Details
Title
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Authors
Keywords
-
Journal
DRUGS
Volume 81, Issue 5, Pages 575-586
Publisher
Springer Science and Business Media LLC
Online
2021-03-26
DOI
10.1007/s40265-021-01487-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
- (2021) Kristin B Highland et al. Lancet Respiratory Medicine
- Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
- (2020) Athol U Wells et al. Lancet Respiratory Medicine
- The natural history of progressive fibrosing interstitial lung diseases
- (2020) K.K. Brown et al. EUROPEAN RESPIRATORY JOURNAL
- Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
- (2020) Joseph A. Lasky et al. ADVANCES IN THERAPY
- Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
- (2020) James R Seibold et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
- (2020) Paolo Cameli et al. Frontiers in Molecular Biosciences
- Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
- (2019) Sven Wind et al. CLINICAL PHARMACOKINETICS
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
- (2019) Oliver Distler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis
- (2019) Timothy M. Dempsey et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
- (2019) Kevin R. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
- (2019) Bridget F. Collins et al. European Respiratory Review
- Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease
- (2018) Elizabeth F. Redente et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial
- (2018) Carlo Vancheri et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2018) Michael Kreuter et al. RESPIRATION
- Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
- (2018) Eva Brunnemer et al. RESPIRATION
- Finding the Target: In Silico and Genetic Screening for Mechanistically Novel Drugs in PAH
- (2018) Brian B Graham et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
- (2018) Martin Kolb et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
- (2018) Bruno Crestani et al. Lancet Respiratory Medicine
- No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone
- (2018) Luca Richeldi et al. EUROPEAN RESPIRATORY JOURNAL
- Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events
- (2018) Elisabeth Bendstrup et al. RESPIRATION
- Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis
- (2018) Kevin K. Brown et al. RESPIRATORY MEDICINE
- Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis
- (2017) Harold R. Collard et al. EUROPEAN RESPIRATORY JOURNAL
- Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
- (2017) Kristell Marzin et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS
- (2016) Ulrich Costabel et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Update of EULAR recommendations for the treatment of systemic sclerosis
- (2016) Otylia Kowal-Bielecka et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
- (2016) Bram Rochwerg et al. BMC Medicine
- Drug Treatment of Idiopathic Pulmonary Fibrosis
- (2016) William J. Canestaro et al. CHEST
- Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
- (2016) Francesco Bonella et al. RESPIRATION
- Subgroup analysis of Asian patients in the INPULSIS®trials of nintedanib in idiopathic pulmonary fibrosis
- (2016) Hiroyuki Taniguchi et al. RESPIROLOGY
- Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
- (2016) Martin Kolb et al. THORAX
- An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
- (2015) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
- (2015) Jingang Huang et al. ANNALS OF THE RHEUMATIC DISEASES
- Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis
- (2015) Gillian M. Keating DRUGS
- Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
- (2015) Lutz Wollin et al. EUROPEAN RESPIRATORY JOURNAL
- Nintedanib: First Global Approval
- (2014) Paul L. McCormack DRUGS
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis
- (2014) Luca Richeldi et al. RESPIRATORY MEDICINE
- Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study
- (2013) Tim Eisen et al. INVESTIGATIONAL NEW DRUGS
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
- (2011) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort
- (2010) Shervin Assassi et al. ARTHRITIS RESEARCH & THERAPY
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started